Table 4.

List of identified ongoing trials to extract radiomic features. Only aims concerning radiomics are mentioned above. In the second column # are the number of patients enrolled retrospectively (R) or prospectively (P). The third column displays the imaging modality (mpMRI=multiparametric magnetic resonance imaging, PSMA/FDG-PET=prostate specific membrane antigen fluorodeoxyglucose positron emission tomography, CT=computer tomography). The fourth column gives an overview of the study's aim(s).

Study	#	Imaging Modality	Aim(s)
NCT03979573	90 (P)	mpMRI	Identification and monitoring of patients with RF in combination with clinical and molecular markers during active surveillance of PCa to reduce discontinuation.
NCT02242773	207 (P)	mpMRI	Correlation of RF with progression during active surveillance and with genomic signatures and other biomarkers.
NCT03180398	20 (P)	mpMRI	Extracted RF are used to identify dominant lesions within the prostate. These RF are monitored longitudinally to analyze their correlation with the local control.
NCT04219059	200 (R)	mpMRI	Evaluates if RF on primitive prostate lesions can describe histological characteristics, lymph node involvement and disease extension.
NCT04343885	140 (P)	PSMA/FDG-PET, CT, bone scans	Prognostic and predictive value RF from PET, CT or bone scans after Lutetium-177 PSMA radionuclide treatment and/ or chemotherapy.